> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs NeuroBo Obesity Drug Phase 1 Trial
- URL: https://www.fdaweb.com/fda-oks-neurobo-obesity-drug-phase-1-trial/
- Published: 2024-02-01T12:00:00.000Z
- Updated: 2026-09-14T14:21:56.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156270

FDA has cleared a NeuroBo Pharmaceuticals IND for a Phase 1 trial of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide 1 receptor and glucagon receptor as a treatment for obesity. The company [says](https://www.neurobopharma.com/news-releases/news-release-details/neurobo-pharmaceuticals-announces-fda-clearance-ind-phase-1?ref=fdaweb.com) it plans to start the trial in the first half of this year.

The statement says DA-1726 is administered once weekly subcutaneously and leads to weight loss through reduced appetite and increased energy expenditure.